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Summary 
The HLA-C locus remains an enigma. The serological polymorphism is poorly defined, HLA-C 
molecules are expressed at the cell surface at about 10% the levels of HLA-A and -B, and their 
importance for antigen presentation to either CDS-bearing T cells or natural killer cells is undear. 
Our understanding of HLA-C polymorphism has also lagged behind that of HLA-A and -B. 
We have applied the polymerase chain reaction to the characterization  of eDNA encoding HLA-C 
antigens. Combining the recent results with previously characterized HLA-C alleles gives a data 
base of 26 sequences, which was used to analyze the nature of HLA-C polymorphism and compare 
it to the variation seen in HLA-A and -B. The sequences form 10 families of alleles that correlate 
well with the patterns of serological crossreactivity, including the C blanks, and all major HLA-C 
allelic families appear to have  been sampled. The families further divide into two groups of HLA-C 
alleles defined on the basis of linked substitutions in the 3' exons. In comparison with HLA-A 
and -B, HLA-C alleles are more closely related to each other, there being less variation in residues 
of the antigen recognition site and more variation at other positions. In particular,  the helix 
of the (xl domain of HLA-C molecules is unusually conserved. Despite the reduced diversity 
in the antigen recognition site, it is evident that HLA-C genes have been the target of past selection 
for polymorphism. Within the antigen recognition site,  it  is  the ol1 domain that is  most 
diagnostic of HLA-C, whereas the o~2 domain is similar to that of HLA-B, the locus to which 
HLA-C is most closely related. In particular,  conserved motifs in the or1 helix and the conserved 
glycine at the base of the B pocket (position 45) provide a combination of features that is uniquely 
found in HLA-C molecules. We hypothesize that these features restrict the peptides bound by 
HLA-C molecules and in this manner reduce the efficiency of HLA-C assembly and expression 
at the cell surface. The overall picture of HLA-C polymorphism obtained from this sampling 
of HLA-C alleles is unlikely to change as further alleles are characterized. 
H 
LA-A and -B heavy chains are polymorphic glycopro- 
teins  that  associate  noncovalently  with  132-micro- 
globulin (B~-m).l The function of these molecules is to bind 
and present antigenic peptides to CTL (reviewed in reference 
1). Although many examples of antigenic peptides presented 
in an aUele-specific  manner by HLA-A or -B molecules have 
been described, the role of the homologous HLA-C mole- 
cules in the immune response is still poorly understood. Due 
to their weak immunogenicity and the lack of specific re- 
agents, serological typing of the products of the HLA-C locus 
has been persistently difficuh, and some 20% of HLA-C al- 
leles type blank in most populations (2-5).  Furthermore, 
HLA-C antigens are expressed on cell surfaces to a much lesser 
extent ('~10%) than either HLA-A or -B (6-8), and exhibit 
1 Abbreviation used in this paper: 13z-m, B2-microglobulin. 
heterogeneity in their carbohydrate moiety (8). In addition, 
analysis of HLA-C heavy chains by IEF reveals an unexplained 
heterogeneity that is not due to sialic acid (7,  9).  HLA-C 
molecules are also distinguished by inefficient assembly with 
/~2-m and slower rate of exocytosis, which presumably con- 
tribute to the lower cell surface expression (10). These differ- 
ences are not the result of lower levels of transcription or 
translation as HLA-C heavy chains are synthesized in amounts 
similar to HLA-A and HLA-B heavy chains (10, 11). 
Analysis of alloreactive responses has shown HLA-C mol- 
ecules can be recognized by the receptors of human CTL, 
both in in vitro culture (12-14) and in allograft rejection (15). 
Furthermore,  EBV-specific cytotoxic T  cells restricted by 
HLA-C have been described (16), and a peptide derived from 
the gag protein of HIV-1 was shown recently to be presented 
by HLA-Cw3 (17). The functional capacity of the Cw3 mol- 
ecule has also been examined in transgenic mice, and examples 
of mouse CTL recognizing both viral peptides presented by 
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results demonstrate  that  HLA-C molecules can participate 
in the immune response, a concept also supported by the as- 
sociation of HLA-C antigens with  susceptibility to disease 
(19-23).  Giissow et  al.  (7),  however,  have  suggested that 
"HLA-C may be dispensable for proper functioning of the 
immune system" and concerns as to the significance of the 
contribution  of HLA-C to protective immunity  compared 
with  HLA-A and B remain  (24,  25). 
The feature that dearly distinguishes HLA-C from HLA-A 
and -B is its low cell surface expression, and in this regard, 
HLA-C is similar  to the H-2L  a molecule (26), which is "ex- 
pressed on the cell surface at levels three to four times lower 
than D a or K d'' (27). In the case of H-2L  d, reduced expres- 
sion correlates with slower transport to the cell surface,  and 
weaker  association  with  32-m  (27).  Analysis  of chimeric 
molecules  formed by exon shuftting  of the H-2D  d and H-2L  a 
genes showed the sequence of the o~1 domain determined the 
level of cell surface expression (28).  Furthermore,  expression 
of H-2L  d at the surface can be increased fourfold by feeding 
cells with an appropriate peptide ligand (29). That all HLA-C 
alleles appear to give low expression at the cell surface (5, 
10) suggests HLA-C heavy chains share sequence motifs that 
confer this property. In this paper, we analyze the sequences 
of HLA-C alleles  to identify such features. 
Molecular  analysis  of HLA-C  polymorphism  has  been 
impeded by the difficulties in serological HLA-C typing and 
in purifying HLA-C proteins. Similarly, the isolation and mo- 
lecular characterization  of HLA-C alleles has lagged behind 
that  of HLA-A and -B alleles.  Application  of the PCR to 
the specific cloning of HLA-C alleles circumvents these prob- 
lems (30, 31) and has facilitated comparison here of 26 HLA-C 
alleles. This analysis has permitted determination of the na- 
ture of HLA-C polymorphism, its comparison with that of 
HLA-A and -B, and the identification of features that might 
determine low cell  surface expression. 
Materials and Methods 
The isolation and characterization of HLA-C cDNA from human 
B cell lines was essentially as described by Ennis et al. (30), except 
that the 3' oligonucleotide primer used in amplification by the PCR 
was derived from a region of the 3' untranslated region that con- 
tained HLA-C-specific substitutions.  The sequences of the two 
primers used in amplification were HLA-SP2: 5' GCC CGT CGA 
CGG ACT CAG AAT CTC CCC AGA CGC CGA G 3' (5' 
primer), and HLA-3pC: 5' CCG CAA GCT TTC GC~ GAG GGA 
ACA CAG GTC AGT GTG GGG AC 3' (3' primer)  (31). This 
strategy, which yields the entire coding region, has been used to 
isolate alleles encoding the previously uncharacterized  Cw4 and 
Cw8 antigens  and novel subtypes of Cwl and Cw3. 
Previously published HLA-C sequences used in this analysis were 
Cw*0101, Cw*0201 (7); Cw*0301 (32); Cw*0102, Cw*0302 (33); 
Cw*02021 (34); Cw*02022 (35); BeWo C.1 (36); C1.9 and C1.10 
(37); CW6P, Cw*0701 (38); Cw*0501 and Cw'1301 (3); Cw*0601 
(39); Cw*0702 (40); Cw*0801 and Cw*0802 (31); Cw*0803 (41); 
Cw'1201 (42); Cw'1202 and Cw'1401 (4); HLA-4 (43); and C*X 
(44). World Health Organization  nomenclature for the alleles and 
their previous designations are described in references 45 and 46. 
In comparison with the other 25 HLA-C alleles, Cw*0301 (the 
first C allele sequenced [32]) has an unusually high number of unique 
substitutions.  For HLA-A and -B, a number of such substitutions 
have proved to be the result  of errors or artifacts introduced  in 
cloning and sequencing. Supporting this contention for Cw*0301 
are the results we obtained from sequencing Cw3 from AP, a cell 
line of Korean origin  (33). This  allele (Cw*0302)  differs from 
Cw*0301 by 16 nucleotide substitutions  in the 1,101 base pairs of 
the coding region,  which produce a 10-amino  acid substitution 
(six in the c~1 domain and four in the c~2 domain).  At all six of 
the substitutions  in the c~1 domain,  Cw*0301 has a unique res- 
idue, whereas Cw*0302 is identical to the consensus. Four of the 
positions occur in two pairs (40,41 and 54,55), which could be 
due to localized misordering of the sequence; one of these substi- 
tutions (55) would destroy the conserved salt bridge that links the 
st and c~2 helices; a fifth substitution  (69) places a proline in the 
c~1 helix providing additional reason for concern. Within the c~2 
domain, the published Cw*0301 sequence placed a unique glycine 
at 181, which was subsequently corrected to the consensus residue 
arginine (47). Of the remaining  three positions of difference, 95 
and 116 are consistent with the general pattern of diversity of class 
I molecules and are those most likely to represent real differences. 
Asparagane 137 is unique to Cw*0301. The nucleotides at these 
positions in both Cw3 sequences are seen in other class I HLA 
sequences and two of the positions point into the peptide binding 
groove. Thus, in our analyses, the Cw*0301 sequence  has not always 
been included. 
Results 
The sequences of 26 alleles of the HLA-C locus have now 
been determined.  This base of data is the result of indepen- 
dent research from 15 laboratories (2, 3, 6, 7, 31-44, 48, 49), 
and in some instances,  clones encoding HLA-C alleles have 
emerged from the study of immunological phenomena not 
immediately related to class I HLA molecules (36, 49). De- 
termination of serologicaUy well-characterized HLA-C alleles 
now permits identification  of these sequences of unknown 
HLA-C alleles. 
HLA-Cw4 Is Identical to the PL208 Clone Isolated on the Basis 
of Serological Crossreactivity with gp120.  The Cw4-encoding 
allele Cw*0401 was characterized from the mutant B cell line 
C1R of Caucasian origin, which expresses Cw4 as the only 
serologicaUy detected class I antigen (48). Subsequently, we 
and Watkins et al.  (41, 44) cloned the identical Cw4 allele 
from cell lines derived from Native South Americans  and 
poorly characterized for HLA-C alleles. Thus, the Cw*0401 
allele is widely dispersed in human populations,  and in the 
C1R mutant,  the Cw4 gene has not undergone mutation. 
Beretta et al. (49) identified a mAb (M38) with specificity 
for both the gp120 of HIV-1 and a surface protein of acti- 
vated lymphocytes and monocytes. This group subsequently 
cloned a cDNA encoding the M38 antigen  from a library 
made from PHA-activated lymphocytes of unknown HLA 
type (50). This cDNA "revealed a high degree of homology 
with the class I MHC gene family" The sequence being "not 
identical to any of the already sequenced alleles" but having 
maximal homology to alleles of the HLA-C locus. We dis- 
covered the sequence of this PL208 clone to be identical to 
Cw*0401. Grassi et al.  (50) found the M38~antibody binds 
to cells from individuals of different HLA type, showing that 
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antibody (49).  In their comparison of the PL208 sequence 
Grassi et al. (50) mistakenly labeled the HLA-4 sequence (43), 
which is closely related to Cw7, as Cw4, and thus from their 
analysis,  it appeared PL208 was not identical to Cw4. 
HLA-Cw4 Is Related  to the BeWo C.I  Clone Isolated frora 
a Choriocarcinoma Cell Link  The BeWo C.1 sequence reported 
by Ellis et al. (36), which was obtained from the "HLA-A,B,C- 
negative" choriocarcinoma cell line BeWo, is now seen to be 
most closely related to Cw*0401. Amino acid substitutions 
at five positions, 49,  50,  and 68 in the c~1 domain and 155 
in the o~2 domain, and 340 in the cytoplasmic domain, dis- 
tinguish the two sequences (Fig.  1).  Thus,  BeWo C.1  ap- 
pears to be a subtype of Cw4. Ellis et al. (36) found it "im- 
possible to obtain a tissue type for BeWo ceils" suggesting 
the amino acid differences between the subtypes may have 
an affect on serological determinants. Ahematively, the c~6c~ 
ties in typing this nonlymphoid cell may be due to low cell 
surface density of the class I molecules. 
HLA-Cw8 and Cw3 Sequences.  We have cloned alleles cor- 
responding to the Cw8 antigen from cell lines of Caucasian 
and Native American origin, and partial sequences of two 
alleles were previously reported (33) in an analysis of the sero- 
logical properties of the HLA-B46 molecule. Three subtypes 
have now been defined, which differ by one to four amino 
acid substitutions￿9 The Caucasian subtype of Cw8 (Cw*0802) 
differs by just a single amino acid from the HLA-C sequence 
reported by Bronson et al. (51), and which was derived from 
a yeast artificial chromosome (YAC) library made from the 
CGM1 cell line. The Cw*0801 subtype, which was isolated 
from a Native North American, is identical to the sequence 
that we erroneously thought corresponded to the Cwll an- 
tigen (33,  52). The HLA-Cwll antigen is now known not 
to define a unique allele but an epitope shared by B46 and 
Cwl molecules. The third subtype Cw*0803 was obtained 
from a Native South American of the Kaingang tribe (41). 
Two Groups of HLA-C Sequences.  Comparison of the 26 
HLA-C sequences reveals a group of three that stand out from 
the rest: Cw'0701, HLA-4, and Cw*0702 (previously called 
JY328 [40]).  The HLA-4 and Cw*0702 sequences were de- 
rived from serologically uncharacterized alleles (40, 43), but 
their striking sequence similarity to HLA-Cw*0701 shows 
they comprise a group of Cw7 subtypes. Frequency histo- 
grams representing the distribution of nucleotide differences 
between pairs of HLA-C alleles dearly show the Cw7 se- 
quences form a distinct group (Fig.  2), and this can also be 
seen with a dendogram calculated using the unweighted pair- 
group method using arithmetic averages (53) from the HLA-C 
sequences (Fig.  3). Characteristic of the Cw7 group is a se- 
ries of 16 nucleotide substitutions spread through exons 4-8, 
which produce 11 amino acid substitutions (Fig.  1). These 
substitutions  are  common  to  Cw*0701,  Cw*0702,  and 
HLA-4, but  are found in no other HLA-C sequences.  An 
additional three nucleotide substitutions, of which two are 
coding changes, are unique to two of the three sequences. 
The independent determination of the JY328, HLA-4, and 
Cw7 sequences in different laboratories (38,  40,  43)  gives 
confidence to the validity of this unique set of linked substi- 
tutions;  furthermore, they have also been found in gorilla 
homologues of HLA-C (54). HLA-Cw7 is the most common 
HLA-C antigen in many human populations (2), having a 
frequency of '~40% in Caucasians,  for example (22).  Thus, 
the representation at the population level of the unusual Cw7 
sequence is much greater than appreciated from simple com- 
parisons in which alleles are given equal weight irrespective 
of frequency (55). 
Locus-specific  substitutions are found in the 3' exons and 
the 3' untranslated regions of class I HLA genes (43, 52, 56, 
57), suggesting the Cw7 subtypes may represent a locus dis- 
tinct from that encoding the other HLA-C antigens. Indeed, 
an RFLP analysis by Duceman et al. (58) suggested that was 
the case for the JY328 gene. A more recent study, however, 
favors the interpretation that all HLA-C antigens are encoded 
by the alleles of a single locus (59).  In that case the linked 
substitutions in the Cw7 alleles may have originated from 
another locus and been introduced into a C  allele by gene 
conversion. 
Correlation of Structure and Serology.  For the most part, 
the structural relationships defined by the dendogram (Fig. 
3) are consistent with the patterns of HLA-C serological cross- 
reactivity. All alldes serologically typed as the same antigen 
group together, for example, the various subtypes of the sero- 
logically defined antigens. Similarly, the Cw5 and Cw8 an- 
tigens that are serologically crossreactive (60) are found to 
be most closely related in sequence.  An exception to such 
correlations is provided by the Cw4 and Cw6 antigens, which 
are serologically crossreactive (61) but quite divergent in se- 
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quence. Amino acid substitutions that correlate with known 
serological reactivities are shown in Table 1. The Cwl, Cw2, 
and Cw3 proteins have the greatest numbers of unique sub- 
stitutions, probably explaining why they were most easy to 
define by serology. 
Approximately 20% of HLAoC alleles cannot be serologi- 
cally typed (2), and structures for a number of these blank 
alleles have been determined  (3, 4, 42).  That designated  as 
Cw'1401 (Cbl) groups with the Cwl subtypes, while three 
others,  Cw'1201  (Cx52),  Cw'1202  (Cb2),  and Cw'1301 
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Cw*1202  ............................  LM ..........  Cw*1202 
Cw*1301  ........................................  Cw*1301 
Cw*1401  ........................................  Cw*1401 
CI.10  ........................................  CI.10 
C1.9  .............................  M ..........  Ci.9 
C*X  .............................  M ..........  C*X 
CONSENSUS  EPSSQPTIPIVGIVA~LAVLAVLAVLGAWAVVMCRRKSS  CONSENSUS 
320  330  340 
GGKGGSCSQAASSNSAQGSDESLIACKA* 
............................. 
............................. 
............................. 
............................. 
............................. 
............................. 
............................. 
............................. 
..........................  S--- 
............................. 
............................. 
............................. 
...........  C ............  T .... 
...........  C ............  T .... 
...........  C  ............  T  .... 
............................. 
............................  , 
............................. 
......................  ..~176 
............................. 
............................. 
............................. 
............................. 
............................. 
............................. 
GGKGGSCSQAASSNSAQGSDESLIACKA* 
Figure 1.  Amino acid sequences of the heavy chains encoded by 26 HLA-C alleles. WHO nomenclature is used for those sequences assigned names. 
A  compete listing of previous  names can be found in references 45 and 46. 
(CwBL18), form a separate group with similarity to the C1.10 
and Cw6 sequences (Fig. 3).  That CL10 groups with Cw6 
is not surprising,  as Cianetti et al.  (37)  typed  the GM637 
fibroblast cell line from which this clone was derived as ei- 
ther Cw6  or Cw7.  The C1.9 and Cw*X  sequences  form 
separate  group that is not closely associated with any sero- 
logicaUy defined antigens.  That the blanks assort into one 
of two groups indicates that most,  if not all,  of the major 
alldic  motifs  at  the HLA-C  locus have been defined. 
Nature of  HLA-CPol2/morphism.  The total number ofpoly- 
941  Zemmour and Parham 15- 
10- 
5- 
c 
O" 
0 
15. 
10- 
5. 
0 
15- 
10- 
J 
O' 
0  20  40  60 
Number of nucleotide substitutions 
Figure 2.  Two groups of HLA-C alleles. The number ofnucleotide sub- 
stitutions between pairs of HLA-C alleles were calculated. Histograms of 
the frequency of these differences  are shown. (a) Distribution when all 
26 HLA-C alleles are included. (b) Distribution when the group of three 
Cw7 subtypes are omitted from the analysis. (c) Distribution of differ- 
ences when one member of the pair is from the Cw7 group and when 
the other is not. 
morphic positions is comparable for HLA-B and -C, with 
HLA-A being somewhat higher. However, when just the o~1 
and o~2 domains are considered, the number is significantly 
less for HLA-C than for either HLA-A or B (Table 2). This 
trend is even stronger if just the functional positions of the 
antigen recognition sites are considered Thus, in comparison 
with HLA-B, the locus to which it is most closely related 
in evolution, HLA-C has less variation in the antigen recog- 
nition site and more variation elsewhere. 
A second measure of relative variation was to compare the 
range and distribution of nucleotide differences between pairs 
of HLA-A, -B, and -C alleles. Although the range of differ- 
ences between alleles at all three loci is remarkably similar, 
[ 
t 
--4 
-  __{{-- 
Antigen 
0w*0701  ) 
HLA-4  Cw 7 
Cw*0702 
Cw*0302  ) 
Cw*0301  Cw 3 
BeWoC.1 ~r  Cw 4 
Cw*0401  J 
Cw*0101  ) 
Cw*0102  Cw 1 
--  Cw'1401 
c*xCI'9  ~  blank 
Cw*02022 t 
Cw'02021  Cw 2 
Cw*0201 
Cw*0803  ) 
Cw*0801  Cw 8 
Cw*0802 
--  Cw*0501  ~-  Cw 5 
Cw'1202  ) 
Cw'1201  blank 
Cw'1301 
C1.10 
Cw*0601  Cw 6 
Figure 3.  A dendogram constructed from the nucleotide sequences of 
the coding regions of HLA-C alleles, using the unweighted pair group 
method using arithmetic averages (48). The serological antigens corre- 
sponding to the different alleles are shown on the right. 
the median and mode are at significantly lower values  for 
the HLA-C distribution (Fig.  4).  The part of the HLA-C 
distribution at higher values, >40, is entirely due to the Cw7 
group (Figs. 2, 4). Thus, HLA-C alleles are, on average, more 
Table  1.  Serological Epitopes 
Potential 
epitope specificity  Amino acid substitutions 
Cwl  K6,  F9, C99 
Cw2  $16,  T211,  W156,  E163 
Cw3  L156, L163, K173 
Cw4  $9,  $11,  W14,  E49 
Cw7  L147, A152, L156 
Cw5  x  Cw8  Q35,  K138,  K177 
Cw4  x  Cw6  A73, N77,  K80 
Cw6  x  Cw7  D9,  $24 
942  Distinctive  Polymorphism at the HLA-C Locus Table  2.  Numbers  of Polymorphic Positions 
External  Cyt.  oll cr  Functional 
0~1 domain  ~2 domain  oe3 domain  domains  T.M domain  domains  All domains  domains  positions 
HLA-A  19"  23  8  50  6  2  58  42  31 
HLA-B  23  20  2  45  3  1  49  43  27 
HLA-C  13  17  8  38  7  2  47  30  15 
Total number of functional positions  -  54. 
* Number of residues that show some polymorphism. 
similar to each other than are HLA-A or -B aUeles. This differ- 
ence is more pronounced when just the domains (oel and oL2) 
forming the antigen recognition site are analyzed in this fashion 
(Fig. 5). The allelic differences are greatest for HLA-B, inter- 
mediate  for HLA-A,  and lowest for HLA-C. 
HLA-A 
20 
10 
0 
60 ￿84 
40 
20 ￿84 
0 
1.5 
10 ￿84 
O' 
0  20  40  60 
Number of nucleoUde substitutions 
Figure 4.  Pairwise  comparison of nucleotide differences  between alleles 
of the HLA-A (top), HLA-B (middle), and HLA-C (bottom) loci. For each 
locus the number of nucleotide substitutions between all pairs of alleles 
are calculated  and their frequency  distributions are shown. The sequences 
of the entire coding regions are compared. 
For HLA-A,  -B, and  -C,  analysis of sequence variability 
by the method of Wu and Kabat (62) shows that positions 
of high variability (equal to or greater than four) are, with 
one exception, at functional positions of the antigen recog- 
nition site.  11, 15, and 7 positions of high variability are found 
for HLA-A, -B, and -C, respectively (Table 3). Moreover, po- 
sition 49 in HLA-C is the exceptional position of high vari- 
ability that is not in the antigen recognition site.  Also ap- 
45" 
30' 
15' 
HLA-A 
| 
O' 
60. 
45. 
30. 
15. 
O. 
25 
20 
15 
I0 
5 
0 
0 
Figure 5. 
HLA-C 
20  40 
Numl~mr  of nuoleottde  subetRutlons 
A similar analysis to that shown in Fig. 4, with the difference 
that only the sequences  of exons 2 and 3 encoding the c~1 and o~z domains 
are compared. 
943  Zemmour and Patham Table  3.  Positions of High  Variability (>4.0) in HLA-A,  -B, and -C Molecules 
Variability 
Position  Location on structure  HLA-A  HLA-B  HLA-C  Potential contact 
cxl domain 
9 
24 
45 
49 
62 
63 
67 
69 
70 
76 
77 
80 
82 
c~2 domain 
95 
97 
99 
114 
116 
152 
156 
163 
/31  11  4  9 
/32  *  7 
/34  *  15  * 
Between/34 and  *  *  5 
short  a  helix 
c~ helix  13  * 
helix  4  * 
ol helix  13  * 
ol helix  *  4  * 
oe helix  6  * 
helix  5  * 
c~ helix  5  5 
c~ helix  5 
ot helix  4  * 
Peptide 
Peptide 
Peptide 
Silent? 
TcK  +  peptide 
Peptide 
Peptide 
TCR 
Peptide 
TCK 
Peptide 
Peptide 
TCK 
/31  5  7  Peptide 
/31  7  13  Peptide 
/31  6  Peptide 
/32  10  5  Peptide 
/32  5  17  12  Peptide 
cx helix  7  4  Peptide 
ct helix  8  5  11  Peptide 
helix  6  4  TCK  +  peptide 
Wu and Kabat variability (62) was calculated for 24 HLA-A, 24 HLA-B, and 24 HLA-C sequences. The variability at each position in a set of 
homologous sequences  is defined  as the number of different  amino acids found at the position divided  by the frequency  of the most common  residue. 
* Conserved position. 
parent is that eight positions that show high variability in 
either HLA-A or -B are conserved in all HLA-C sequences. 
These residues focus on the (~1 helix and result in this ele- 
ment of the antigen recognition site being highly conserved 
in HLA-C molecules. This property undoubtedly contributes 
to the difficulty in the serological definition of HLA-C al- 
leles, as variation in the or1 helix produces many of the epi- 
topes that distinguish HLA-A and -B molecules (63). 
Crystallography has defined six specificity pockets within 
the binding groove that accommodate peptide side chains and 
terminal groups (64-67). Overall, the sequence motifs found 
in these pockets of HLA-C molecules are distinct from those 
in HLA-A and -B. The peptides bound by HLA-C are there- 
fore expected to be distinct.  Although exhibiting a small 
number of positions of high variability, there is at least one 
such position in each of the specificity pockets for HLA-C 
(Fig.  6). 
Analysis of the interaction between HLA-B27 and peptide 
shows the B pocket plays a critical "anchoring" role in binding 
the arginine at position 2, which is common to B27-binding 
peptides (68-70). In particular, the negatively charged glu- 
tamic acid at position 45 at the base of the pocket forms an 
electrostatic interaction with the arginine side chain of the 
peptide. Contrasting with HLA-B molecules for which the 
B pocket is highly diversified, the B pocket of HLA-C mole- 
cules is conserved. Of significance is that residue 45 is a con- 
served glycine that may contribute little to peptide interac- 
tion. Thus, the anchoring role for the B pocket in HLA-B 
could be absent or attenuated in HLAoC. 
In the extraceUular domains there are 12 positions at which 
HLA-C shows variability and where HLA-A and/or -B are 
conserved. None of these is in the antigen recognition site. 
Thus, no residues of the peptide binding groove are uniquely 
variable in HLA-C. In contrast, of 24 residues that are con- 
944  Distinctive  Polymorphism at the HLA-C Locus Cw*0302 
A  pocket  B  pocket  C  pocket 
5  7  1  I  5  6  6  9  1  1  9  2  3  4  6  7  6  6  7  9  9  7  7  7  9 
5  7  9  3  6  9  6  6  4  4  5  7  3  6  O  9  0  3  4  7 
91  3  7 
MY  Y  Y  Y  E  K  Y  L  W  Y  A  V  G  Y  Y  E  K  Q  Y  YQTDR 
Cw*OlOl  .......  C  T  -  F  S  .......  C  F  -  W 
Cw"0201  ........  E  .................... 
Cw'0401  .......  F  T  -  S  ........  F  S  -  A  -  N 
BeWoC.I  .......  F  T  -  S  ........  F  S  -  A  -  N 
Cw*0501  ........  T  ..................  N 
Cw*0601  ........  T  -  D  S  ........  n  -  A  -  W 
Cw*0801  ........  T  .................. 
Cw*0802  ........  T  ................. 
Cw*1201  ........  T  ............  A  - 
Cw*  1202  ........  T  ..............  A  - 
Cw*1301  ........  T  ...............  A  - 
Cw*1401  .......  F  T  -  S  ........  F  S  -  W 
CI.10  ........  T  ................  W 
CI.9  ......  N  -  T  .........  N  ............. 
D  p~ket  E  p~ket 
11191  91111 
55695  71455 
690  S  4726 
LYLYQ  RDWEL 
R  -  C  -  W  -  R 
W  ........  W 
R  -  F  -  N  -  R 
R-  FE  N-  R 
R  ......  N  -  R 
W  ....  W  -  W 
N  .....  N  -  T  - 
N  R  ....  N  -  R 
W  ........  W 
--  W  ........  W 
W  .........  W 
R  -  F  -  W-  R 
Q  ....  W-  A  Q 
F  pocket 
7  1  8  8  1  1  1  i 
7  1  0  4  2  4  4  4 
6  3  3  6  7 
S  S  N  Y  Y  T  K  W 
y  ...... 
N  K  ..... 
N  F  K  ..... 
N  F  K  ..... 
N  F  K  .... 
N  K  ..... 
F  ...... 
F  ...... 
V  ...... 
N  -  L  K  ..... 
Cw'0701  ￿9  ￿9  -  -  -  -  N  - 
Cw*0702  .......  S 
HLA-4  .......  S 
B'3501  .....  N  I  .......  T  F  - 
B'3701  ......  I  S  T  -  H  S  -  T  S  - 
B'2705  ......  I  -  E  -  H  T  -  E  C  - 
B*I501  ......  I  .......  M  S  - 
B'0702  .....  N  I  -  E  -  S  -  E  - 
A*0201  ........  T  .....  M  V  - 
A'2501  .....  N  N  -  R  .....  M  V  - 
A'7401  ......  N  -  T  .....  M  V  - 
A*0101  ......  N  -  R  G  -  -  -  M  M  - 
A*2301  .......  F  T  G  S  -  -  M  V  - 
T  -  |  '  ￿9  -  ....  N  - 
T  -  D  S  .......  S 
-  -  D  S  .......  S 
N  I  N  - 
I  N  S 
I  K  - 
I  N  - 
N  I 
H  - 
N  N  H  - 
N  H  - 
N  H  - 
H  F 
A  .........  L  A  ..........  L 
D  -  A  .......  S  E  L  A  ..........  L 
D  -  A  .......  S  .....  A  ........... 
N  -  Y  ........  V  ........... 
H  N  -  Y  - 
H  K  -  N 
N  -  Y  - 
....  S 
H  -  H  - 
H  - 
H  -  M 
H  -  I 
$  H  -  M 
N  D  -  S  -  N  -  V  D 
H  .....  N  H  -  V  - 
W  .........  W 
R  ....  S  -  R 
H  .......  H-  v- 
Q  W  ......  Q  -  w 
Q  .....  MQ  -  V  - 
R  R  ....  I  R  -  A  R 
H  -  F  -  M  H  -  V  - 
D  -  F  T  ..... 
D  -  D  T  ..... 
y  ...... 
D  -  Y  T  ..... 
A  D  I  ..... 
D  -  D  T  ..... 
N  -  D  T  ..... 
N  A  Y  I  ..... 
Figure 6.  Comparison of the amino acid sequence motifs in the six specificity pockets of the antigen recognition site defined by Saper et al. (67). 
Positions with  variability >4.0 are shown (V).  HLA-A and -B sequences are from references 30, 31, 38,  52, and 85-87. 
served in HLA-C and variable in HLA-A and/or -B,  10 are 
residues that contribute to the specifidty pockets of the binding 
~TOOVe. 
The distribution of silent (synonymous) and replacement 
(nonsynonymous)  nucleotide  substitutions  in  HLA-C  se- 
quences was determined as described by Nei et al.  (71,  72). 
In a previous analysis of 10 HLA-A and 6 HLA-B sequences, 
Hughes and Nei (73) showed replacement substitutions were 
nonrandomly focused on residues of the antigen recognition 
site, thus providing quantitative evidence for selection for the 
Table  4.  Pattern of Nudeotide Substitutions within HLA Sequences 
Antigen  recognition  site  al-~x2  (remainder)  c~3 
(n  -  54)  (n  -  128)  (n  -  92) 
ds  dN  ds  dN  ds  dN 
Cvs.  C 
(21)"  2.3  +  1.4  6.9  _+  1.1  5.2  +  1.2  1.8  •  0.4  3.4  +  1.3  1.2  •  0.4 
(17)  2.2  •  1.4  6.6  •  1.1  4.7  •  1.1  1.7  •  0.4  2.9  •  1.2  1.0  •  0.3 
Bvs.  B 
(31)  4.8  •  2.0  15.1  •  1.6  4.8  •  1.2  1.8  •  0.4  2.1  •  1.1  0.2  •  0.2 
Avs.  A 
(31)  3.8  •  1.7  12.5  •  1.6  3.3  •  1.0  1.3  •  0.4  6.6  •  1.9  1.5  •  0.5 
Mean number of nudeotidr substitutions per 100 synonymous sites (ds) and per 100 nonsynonymous sites (ds).  n  -  Number of codons compared. 
d values are estimated using the Nei and Gojobori method (71). SEM ds and dN are estimated by Nei and Jin's method (72). 
" Number of sequences compared. 
945  Zemmour  and Parham polymorphism.  From analysis of 31 HLA-A and 31 HLA-B 
sequences, we obtained  results similar to those  previously 
reported (Table 4). Analysis of 21 HLA-C sequences by this 
method shows the same trend as seen with HLA-A and -B, 
namely that residues of the antigen recognition  site have a 
predominance  of coding  (nonsynonymous)  substitutions, 
whereas noncoding (synonymous) substitutions predominate 
elsewhere. At nonfunctional  positions  of the r  and o~z do- 
mains, the frequency of synonymous  and nonsynonymous 
substitutions is comparable to that seen for HLA-C. In con- 
trast, at the functional positions, the frequency of both types 
of substitution in HLA-C is about half that seen for HLA-B. 
Whereas the frequency of synonymous substitutions is similar 
in the functional and nonfunctional positions for HLA-A and 
-B, for HLA-C there is a relative suppression of such substi- 
tutions in the functional positions. Thus, there appear to be 
at least two factors operating on the functional sites of HLA-C 
antigen recognition  site: one to select for amino acid substi- 
tution and the other to maintain nucleotide sequence homo- 
geneity. 
Dividing the functional positions  into the oq and o~ do- 
mains shows  suppression of substitutions  is focused on the 
o~t  domain  (Table 5).  Further subdivision  into  the  six 
specificity pockets (67) reveals that in the A, B, and D pockets, 
there is little evidence for selection for amino acid diversity 
in HLA-C molecules. The C pocket is unusual in that silent 
substitutions  are  absent. The  sequence  motifs  found  for 
HLA-C molecules in the C pocket are not found in HLA-A 
or -B molecules  (Fig. 6). 
Shared Features of HLA-C Molecules.  HLA-C molecules 
share the property of low cell surface expression, despite levels 
of heavy chain production comparable to HLA-A and -B (10, 
11, 74). Therefore, common features of the HLA-C sequences, 
not shared with HLA-A or -B heavy chains, must underlie 
this behavior. Residues conserved in all HLA-C sequences 
but not found in HLA-A or -B sequences provide candidates 
for such features. 
No  residues of the  c~  and c~z domains  strictly  fit  this 
criterion. In particular, the c~z sequences of HLA-C are very 
similar in their sequence motifs to those found in HLA-B 
o~z domains.  Characteristic C  features exist  in o~, but ex- 
ceptional HLA-B alldes also share some of these features. Gly- 
cine 45 and valine 52 are common to all HLA-C and to HLA- 
B54, but are found in no other HLA-A or B heavy chains 
(75). Similarly, the KYRV motif of residues 66, 67, 69, and 
76  of the c~  hdix is conserved in  HLA-C (proline 69  in 
Cw*0301 is probably an error) and absent in all HLA-A and 
-B molecules except B46  (reference 33).  B54 and B46 both 
have dusters of substitutions that shared with HLA-C alldes 
and were formed by gene conversions between Cwl  and, 
respectively, B55 and B62 (33,  75).  As both these B alldes 
exhibit normal expression, neither glycine 45, valine 52, nor 
the o~1 helical motif is sufficient to reduce expression. How- 
ever, it is possible that the combination  of these features is 
important. 
Three positions in the c~3 domain, E183, G239, and E268, 
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946  Distinctive Polymorphism  at the HLA-C Locus distinguish HLA-C from HLA-A and -B. Position 239 is part 
of a loop that joins two 3  strands,  nos. 4 and 5, which are 
the sites of interaction with fl2-m (64,  67).  The size and 
charge differences between the glycine at  this position in 
HLA-C and the arginine found in HLA-B could have an 
influence on the association  with fl2-m. In HLA-A2, argi- 
nine 181 forms a salt bridge with aspartate 183 and this com- 
bination of residues is conserved in HLA-B. Substitution of 
glutamate for aspartate at 183 in HLA-C might perturb this 
salt bridge and the interaction between the oe2 and o~3 do- 
mains. Glutamate 268, which is located on the seventh B strand 
of the o~3 domain, is surrounded by two proline residues. In 
all HLA-A and -B heavy chains this glutamate is replaced by 
the oppositely charged lysine. In the vicinity is glutamate 
264,  which contacts threonine 182 in the HLA-A2 struc- 
ture (67). 
Within the cytoplasmic domains are four HLA-C-specific 
residues. These comprise cysteine 321, asparagine 328, gluta- 
mate 335, and isoleucine 338. Of these, cysteine 321 replaces 
a tyrosine in HLA-A and -B molecules that can be phos- 
phorylated in vitro (76). These substitutions could possibly 
affect interactions with cytoplasmic proteins or other mem- 
brane components. 
Discussion 
In comparison with HLA-A and -B, the HLA-C locus has 
been studied less and remains poorly understood. Here, we 
present the first extensive analysis of the polymorphism of 
HLA-C alleles. It reveals that the serological description of 
HLA-C antigens generally reflects the underlying structures 
of the alleles, which are variations on 10 basic motifs. Al- 
though some 20%  of HLA-C alleles cannot be defined by 
serological HLA typing, these form two groups, suggesting 
the blank does not encompass a multitude of undiscovered 
alleles. Overall, there is good indication that the 26 alleles 
analyzed here are representative  of the HLA-C alleles to be 
found in human populations and that few, if any, distinctive 
motifs remain to be found. 
The hallmark of class I antigen-presenting molecules is their 
polymorphism, which crystallography has shown is concen- 
trated in functional positions of the antigen recognition site. 
Pairs  of HLA-C  alleles show fewer differences  than their 
HLA-A and -B homologues, and this property is reflected 
in a greater homogeneity  of the antigen recognition site. Con- 
servation of sequence in the oll helix and in the B pocket 
is particularly striking. 
Despite similar levels of mRNA and heavy chain protein 
(10, 11, 74), cell surface expression of HLA-C molecules is 
'~10% that of HLA-A and -B. This appears to be true for 
all HLA-C alleles, and one goal of our analysis was to iden- 
tify features shared by HLA-C molecules that could account 
for this distinguishing property. Candidates are found in the 
c~1, a3, and cytoplasmic domains, but it is those of the o~1 
domain that are most impressive. These residues largely overlap 
with  the  conserved residues  of the  o~i  helix  and  the  B 
pocket, raising the possibility that inefficient  assembly and 
cell surface expression  of HLA-C molecules is primarily a 
failure in the binding of peptides. This could be due to an 
intrinsic property of the antigen binding groove of HLA-C 
molecules, which have low affinity for the majority of pep- 
tides generated from endogenous proteins. The conserved fea- 
tures of the pockets formed by the c~1 domain could be in- 
strumental  in  producing  such  binding  properties.  As  a 
consequence, HLA-C may selectively bind a restricted set of 
peptides, perhaps those more commonly in the sequences of 
foreign, rather than self-proteins. Selectivity in the proteases 
that produce antigenic peptides or in the peptides delivered 
to the endoplasmic reticulum (ER) could act to restrict the 
supply of HLA-C binding peptides in the Elk. The routine 
molecule H-2L  a exhibits inefficient  cell surface expression, 
which can be enhanced by external provision of appropriate 
peptides (29). It will be important to see if the same is true 
for HLA-C and if viral infection acts to increase HLA-C ex- 
pression through this mechanism. 
Low cell surface expression of HLA-C may not result from 
a deficiency in binding peptides but from interactions of the 
HLA-C heavy chain with other components that contribute 
to the assembly and transport of class I molecules. For ex- 
ample, if HLA-C were to have a weaker interaction with 
32-m, or a stronger interaction with the heavy chain binding 
chaperonin (77), than HLA-A or -B, then expression would 
be predicted to be reduced. 
Previous analysis of class I HLA genes and pseudogenes 
has correlated function with polymorphism. Thus, the HLA-A 
and -B genes, which function in antigen presentation to T 
cells,  are  highly polymorphic, whereas  the  pseudogenes, 
HLA-H and J, are conserved (25, 78, 79). HLA-C is inter- 
mediate in character  both in level of expression and diver- 
sification.  This property led to suggestions that HLA-C is 
less functional than HLA-A or -B, a dispensable or declining 
locus (7, 24, 25). Alternatively, HLA-C could be a more re- 
cently formed locus that is still undergoing improvement. 
From the evidence available it seems clear that HLA-C is 
not a defunct class I locus. HLA-C molecules bind peptides 
and interact with TCKs in a variety of experimental systems 
(12-18).  Moreover,  HLA-C alleles are correlated with sus- 
ceptibility to diseases believed to be autoimmune in nature 
(Psoriasis vulgaris  for example)  (21, 80). 
The low cell surface expression may represent an adapta- 
tion giving HLA-C molecules complementary functions to 
those of HLA-A and -B. For example, by not being saturated 
with endogenous peptides, HLA-C may be poised to present 
particular viral peptides. The low expression would be ex- 
pected to influence thymic selection, and in this manner may 
enable distinctive sets of T  cells (high affinity, perhaps) to 
be selected by HLA-C. In this regard, it is worth noting that 
residues of the oe3 domain important for CD8 interactions 
(81, 82) are preserved in HLA-C molecules, although a di- 
rect demonstration for the interaction between HLA-C mol- 
ecules and CD8 has yet to be made. 
Recent  studies on  NK  cell  specificity  have  implicated 
947  Zemmour  and Parham HLA-C molecules in the negative regulation of allotypic NK 
clones (83). In this regard, the unusual features of the C pocket 
of HLA-C are of particular interest, as HLA-A2 has been 
shown to poorly inhibit NK cells due to a unique histidine 
at position 74 in the C  pocket (84).  Moreover,  Asahina et 
al. (80) have shown that susceptibility to psoriasis correlates 
with the presence of alanine at position 73 in the C pocket 
of HLA-C molecules. 
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